Paroxetine
( DrugBank: Paroxetine / KEGG DRUG: Paroxetine hydrochloride hemihydrate, Paroxetine, Paroxetine hydrochloride, Paroxetine mesylate )
4 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 3 |
13 | Multiple sclerosis | 1 |
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 8 |
85 | Idiopathic interstitial pneumonia | 1 |
6. Parkinson disease
Clinical trials : 2,586 / Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,543 / Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
85. Idiopathic interstitial pneumonia
Clinical trials : 723 / Drugs : 411 - (DrugBank : 126) / Drug target genes : 104 - Drug target pathways : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|